Biotech Values

[DewDiligence]

New Survey: Lilly’s Solanezumab

Please see #msg-80358484 for background info.


Q1: Will LLY conduct new phase-3 studies for Solanezumab in mild AD?

a) Yes
b) No


Q2: Based on the prior phase-3 data, should LLY conduct new phase-3 studies for Solanezumab in mild AD?

a) Yes
b) No


Q3: All told, what is the probability that Solanezumab makes it to market and sells $1B+ in peak annual sales?

a) Less than 5%
b) 5-24.9%
c) 25-49.9%
d) 50-74.9%
e) 75% or more


To vote, go to http://investorshub.advfn.com/boards/board_surveymenu.asp?board_id=1418 and select survey #149.

p.s. You may vote at any time in any survey where you have not already voted.